Tardive dyskinesia therapy access patterns
Approved VMAT2 inhibitor therapy for tardive dyskinesia continues to expand but underdiagnosis remains the primary gap.
VMAT2 inhibitor therapy for tardive dyskinesia is approved, effective, and underutilised. The persistent constraint is recognition: TD is underdiagnosed in primary psychiatric care, and patients on long-term antipsychotic therapy are not screened systematically. The commercial story is an access-and-recognition story rather than a clinical-evidence story.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is spasticity?
- SnapshotDementia subtype therapy reference (2026)
- ExplainedAcute ischemic stroke explained
TreatmentDiagnosisAccessPatient journey
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.